Literature DB >> 12149357

Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients.

Heli Piiparinen1, Krister Höckerstedt, Maija Lappalainen, Jukka Suni, Irmeli Lautenschlager.   

Abstract

A quantitative PCR test, the Cobas Amplicor CMV Monitor, was used for the monitoring of viral load in the peripheral blood of 27 individual liver transplant patients and correlated with cytomegalovirus (CMV) pp65 antigenemia. Altogether, 243 specimens were analyzed. During the first 3 months, 20 patients showed PCR positivity which correlated with pp65 antigenemia. Of those, 13 patients developed symptomatic CMV infection 27 to 52 days after transplantation, with a significantly higher peak viral load in PCR and in pp65 assay compared with the seven asymptomatic infections (median 10,200 versus 2,240 copies/ml, P < 0.05, and median 100 versus 30 pp65-positive cells/50,000 leukocytes, P < 0.01). Five were primary infections of D+/R- cases (donor CMV seropositive and recipient seronegative) and demonstrated, except in one case, a high peak viral load (>10,000 copies/ml; range, 10,200 to 21,600 copies, and > or =50 positive cells, range, 50 to 800 cells). The peak viral loads of the six D+/R+ patients with symptomatic infection varied widely (range, 2,290 to 126,000 copies and 50 to 300 positive cells). Two D-/R+ patients developed symptomatic infection with a lower viral load (range, 1,120 to 6,510 copies and 25 to 100 positive cells). All symptomatic infections were successfully treated with ganciclovir. The asymptomatic infections all in D+/R+ patients with low copy numbers (<5,500 copies) were monitored until CMV disappeared. One of the seven PCR-negative patients had one sample with low antigenemia, but the subsequent specimens were all negative. The time-related correlation of the two methods was also good. In summary, quantitative PCR could equally well be used as the CMV pp65 assay for the monitoring of viral load in individual transplant patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149357      PMCID: PMC120691          DOI: 10.1128/JCM.40.8.2945-2952.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

Review 1.  Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.

Authors:  V C Emery
Journal:  Rev Med Virol       Date:  2001 Mar-Apr       Impact factor: 6.989

Review 2.  Prevention of cytomegalovirus disease in recipients of solid-organ transplants.

Authors:  C V Paya
Journal:  Clin Infect Dis       Date:  2001-02-06       Impact factor: 9.079

3.  Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients.

Authors:  M Guiver; A J Fox; K Mutton; N Mogulkoc; J Egan
Journal:  Transplantation       Date:  2001-06-15       Impact factor: 4.939

4.  Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation--a report of 130 consecutive patients.

Authors:  A P van den Berg; W van der Bij; W J van Son; J Anema; M van der Giessen; J Schirm; A M Tegzess; T H The
Journal:  Transplantation       Date:  1989-12       Impact factor: 4.939

Review 5.  Cytomegalovirus antigenemia.

Authors:  T H The; W van der Bij; A P van den Berg; M van der Giessen; J Weits; H G Sprenger; W J van Son
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

6.  Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation.

Authors:  G Boivin; R Bélanger; R Delage; C Béliveau; C Demers; N Goyette; J Roy
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

7.  Comparison of plasma polymerase chain reaction and pp65-antigenemia assay in the quantification of cytomegalovirus in liver and kidney transplant patients.

Authors:  H Piiparinen; K Höckerstedt; C Grönhagen-Riska; M Lappalainen; J Suni; I Lautenschlager
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

8.  Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants.

Authors:  W Preiser; S Bräuninger; R Schwerdtfeger; U Ayliffe; J A Garson; N S Brink; S Franck; H W Doerr; H F Rabenau
Journal:  J Clin Virol       Date:  2001-01       Impact factor: 3.168

9.  Differences between the quantitative antigenemia assay and the cobas amplicor monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients.

Authors:  J Flexman; I Kay; R Fonte; R Herrmann; E Gabbay; S Palladino
Journal:  J Med Virol       Date:  2001-07       Impact factor: 2.327

10.  The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients.

Authors:  P K Koskinen; M S Nieminen; S P Mattila; P J Häyry; I T Lautenschlager
Journal:  Transplantation       Date:  1993-03       Impact factor: 4.939

View more
  4 in total

Review 1.  Herpesvirus infections in organ transplant recipients.

Authors:  Frank J Jenkins; David T Rowe; Charles R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

2.  Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation.

Authors:  Xiaoli L Pang; Linda Chui; Jayne Fenton; Barbara LeBlanc; Jutta K Preiksaitis
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection.

Authors:  Jayant S Kalpoe; Aloys C M Kroes; Menno D de Jong; Janke Schinkel; Caroline S de Brouwer; Matthias F C Beersma; Eric C J Claas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients.

Authors:  Elisabetta Cariani; Caterina P Pollara; Barbara Valloncini; Francesca Perandin; Carlo Bonfanti; Nino Manca
Journal:  BMC Infect Dis       Date:  2007-11-23       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.